The Food and Drug Administration expanded emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12 to 15 years of age on May 10, 2021. The Centers for Disease Control and Prevention followed with recommendations endorsing use in this age group after their advisory group meeting on May 12. The American Academy of Pediatrics also supports this decision.